Kuesap J, Suphakhonchuwong N, Eksonthi B, Huaihongthong S
Malar J. 2025; 24(1):63.
PMID: 40016697
PMC: 11866859.
DOI: 10.1186/s12936-025-05305-w.
Acquah F, Adjah J, Williamson K, Amoah L
Infect Immun. 2019; 87(6).
PMID: 30962400
PMC: 6529669.
DOI: 10.1128/IAI.00775-18.
Canepa G, Molina-Cruz A, Yenkoidiok-Douti L, Calvo E, Williams A, Burkhardt M
NPJ Vaccines. 2018; 3:26.
PMID: 30002917
PMC: 6039440.
DOI: 10.1038/s41541-018-0065-5.
Datta D, Bansal G, Grasperge B, Martin D, Philipp M, Gerloff D
Vaccine. 2017; 35(50):7049-7056.
PMID: 29132995
PMC: 5728386.
DOI: 10.1016/j.vaccine.2017.10.042.
Boes A, Spiegel H, Kastilan R, Bethke S, Voepel N, Chudobova I
Malar J. 2016; 15(1):279.
PMID: 27188716
PMC: 4869186.
DOI: 10.1186/s12936-016-1328-0.
Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail Challenge.
Boes A, Spiegel H, Voepel N, Edgue G, Beiss V, Kapelski S
PLoS One. 2015; 10(7):e0131456.
PMID: 26147206
PMC: 4492585.
DOI: 10.1371/journal.pone.0131456.
A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
Goodman A, Blagborough A, Biswas S, Wu Y, Hill A, Sinden R
PLoS One. 2012; 6(12):e29428.
PMID: 22216279
PMC: 3247263.
DOI: 10.1371/journal.pone.0029428.
In vitro generation of Plasmodium falciparum ookinetes.
Bounkeua V, Li F, Vinetz J
Am J Trop Med Hyg. 2010; 83(6):1187-94.
PMID: 21118920
PMC: 2990030.
DOI: 10.4269/ajtmh.2010.10-0433.
Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity.
Diallo M, Toure A, Traore S, Niare O, Kassambara L, Konare A
Malar J. 2008; 7:248.
PMID: 19055715
PMC: 2640402.
DOI: 10.1186/1475-2875-7-248.
Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
Coban C, Ishii K, Stowers A, Keister D, Klinman D, Kumar N
Infect Immun. 2003; 72(1):584-8.
PMID: 14688140
PMC: 344005.
DOI: 10.1128/IAI.72.1.584-588.2004.
Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
Coban C, Philipp M, Purcell J, Keister D, Okulate M, Martin D
Infect Immun. 2003; 72(1):253-9.
PMID: 14688103
PMC: 344004.
DOI: 10.1128/IAI.72.1.253-259.2004.
A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.
Stowers A, Keister D, Muratova O, Kaslow D
Infect Immun. 2000; 68(10):5530-8.
PMID: 10992450
PMC: 101502.
DOI: 10.1128/IAI.68.10.5530-5538.2000.
Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum.
Black C, Wang L, Hibbs A, Werner E, Coppel R
Infect Immun. 1999; 67(5):2075-81.
PMID: 10225857
PMC: 115940.
DOI: 10.1128/IAI.67.5.2075-2081.1999.
Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.
Lobo C, Dhar R, Kumar N
Infect Immun. 1999; 67(4):1688-93.
PMID: 10085005
PMC: 96515.
DOI: 10.1128/IAI.67.4.1688-1693.1999.
Isolation and functional characterization of two distinct sexual-stage-specific promoters of the human malaria parasite Plasmodium falciparum.
Dechering K, Kaan A, Mbacham W, Wirth D, Eling W, Konings R
Mol Cell Biol. 1999; 19(2):967-78.
PMID: 9891033
PMC: 116028.
DOI: 10.1128/MCB.19.2.967.
A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain.
Marshall V, Silva A, Foley M, Cranmer S, Wang L, McColl D
Infect Immun. 1997; 65(11):4460-7.
PMID: 9353020
PMC: 175641.
DOI: 10.1128/iai.65.11.4460-4467.1997.
Malaria vaccines.
Amador R, Patarroyo M
J Clin Immunol. 1996; 16(4):183-9.
PMID: 8840219
DOI: 10.1007/BF01541223.
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
Tine J, Lanar D, Smith D, Wellde B, Schultheiss P, Ware L
Infect Immun. 1996; 64(9):3833-44.
PMID: 8751936
PMC: 174300.
DOI: 10.1128/iai.64.9.3833-3844.1996.
Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies.
Duffy P, Pimenta P, Kaslow D
J Exp Med. 1993; 177(2):505-10.
PMID: 8426118
PMC: 2190907.
DOI: 10.1084/jem.177.2.505.
Pfs2400 can mediate antibody-dependent malaria transmission inhibition and may be the Plasmodium falciparum 11.1 gene product.
Feng Z, Hoffmann R, Nussenzweig R, Tsuji M, Fujioka H, Aikawa M
J Exp Med. 1993; 177(2):273-81.
PMID: 8426106
PMC: 2190917.
DOI: 10.1084/jem.177.2.273.